Bremelanotide maintains long-term efficacy and safety for hypoactive sexual desire disorder in premenopausal women
Background
Hypoactive sexual desire disorder (HSDD) is characterized by a persistent or recurrent deficiency or absence of sexual fantasies and desire for sexual activity, causing significant distress. It affects a substantial number of premenopausal women, impacting quality of life and relationships. Current treatment options are limited, often with inconsistent efficacy or undesirable side effects. Bremelanotide, a melanocortin 4 receptor (MC4R) agonist, offers a novel mechanism by modulating central nervous system pathways involved in sexual arousal and desire, addressing a critical gap in HSDD management.
Study Design
This study was a 52-week open-label extension (OLE) of two parallel phase 3 trials (RECONNECT 301 and 302) evaluating bremelanotide for HSDD. Women who completed the 24-week double-blind core phase and had no serious adverse events were eligible. A total of 684 patients enrolled in the OLE from 856 eligible, with 272 completing the full 52 weeks. Efficacy was assessed using coprimary endpoints from the core phase: the Female Sexual Function Index-desire domain score (FSFI-desire) and Female Sexual Distress Scale-Desire/Arousal/Orgasm item 13 (FSDS-DAO item 13). All adverse events were collected.
Results
Bremelanotide demonstrated sustained improvements in sexual desire and reduced distress over the 52-week open-label extension. For patients who received bremelanotide during the core phase, the change in FSFI-desire domain score from baseline to the end of the OLE ranged from 1.25 to 1.30. In comparison, those who received placebo during the core phase showed a change of 0.70 to 0.77 upon switching to bremelanotide in the OLE. Similarly, the change in FSDS-DAO item 13 was -1.4 to -1.7 for the original bremelanotide group and -0.9 for the original placebo group. The most common treatment-emergent adverse events considered related to bremelanotide were nausea (40.4%), flushing (20.6%), and headache (12.0%).
Key Findings
- Bremelanotide sustained improvements in FSFI-desire scores by 1.25 to 1.30 over 52 weeks.
- Bremelanotide reduced FSDS-DAO item 13 distress scores by -1.4 to -1.7 over 52 weeks.
- Nausea was the most common adverse event at 40.4%, followed by flushing (20.6%) and headache (12.0%).
- Only severe adverse event experienced by more than one participant was nausea during the open-label extension.
- Patients initially on placebo showed improvements in FSFI-desire (0.70-0.77) and FSDS-DAO (-0.9) upon switching to bremelanotide.
Why It Matters
This study provides crucial evidence for the long-term safety and sustained efficacy of bremelanotide in managing hypoactive sexual desire disorder in premenopausal women. The continued improvement in sexual desire and reduction in distress over 52 weeks suggests that bremelanotide can be a viable long-term treatment option, offering hope for individuals seeking sustained relief from HSDD symptoms. The consistent safety profile, with common adverse events like nausea and flushing being generally manageable, supports its practical application. This data helps clinicians and patients make informed decisions about long-term treatment strategies, potentially improving adherence and overall quality of life for those affected by HSDD.
bremelanotide
hsdd
sexual-health
women's-health
phase-3
long-term